Richard Benjamin Shares Results of The ReCePI Phase III Clinical Study
Richard Benjamin, Chief Medical Officer at Cerus Corporation, shared on LinkedIn:
”The results of the ReCePI Phase III clinical study are now published.
A hearty congratulations to the many contributors and patients who have advanced the field of pathogen reduction for red blood cells (RBCs).
While transfusions are generally considered safe, they are always at risk for newly emerging infections (think historically of HIV, WNV, Zika, etc.) and for threats that are not covered by current testing (e.g., bacteria, malaria, etc.).
Technologies are FDA-approved to safeguard platelet and plasma transfusions, leaving an obvious gap with the most commonly transfused RBC components.
This work is bringing RBC pathogen reduction to reality and would not have been possible without generous funding from BARDA, a US agency with true foresight to protect patients against future and current threats to transfusion safety.”
Read the full article here.
Article: Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Authors: Michael E. Sekela, Edward L. Snyder, Ian J. Welsby, Yoshiya Toyoda, Mohamed Alsammak, Neel R. Sodha, Thomas M. Beaver, J. Peter R. Pelletier, James D. Gorham, John S. McNeil, Roman M. Sniecinski, Ronald G. Pearl, Gregory A. Nuttall, Ravi Sarode, T. Brett Reece, Richard Benjamin, and the ReCePI Study Collaborators
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 21, 2025, 03:503 Questions With Abigail Ajanel Gomez – Touch Haematology Future Leader 2025
-
Oct 21, 2025, 01:57Mohamed Reda: Clotting Factors — The Key Players in Blood Coagulation
-
Oct 22, 2025, 10:35Evaluating a Novel Human Fibrinogen Concentrate (BT524) for Congenital Fibrinogen Deficiency
-
Oct 22, 2025, 09:37Jurjen Krommenhoek and Colleagues Propose a Clinical Care Pathway for Major Bleeding Survivors
-
Oct 22, 2025, 09:32Ishac Nazy: Proud Moment For Our Team!
-
Oct 22, 2025, 09:16Richard Benjamin Shares Results of The ReCePI Phase III Clinical Study
-
Oct 21, 2025, 11:13Hanny Al Samkari's Commentary on Iron Deficiency Anemia in Inherited Bleeding Disorders
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 21, 2025, 06:18Katerina Akassoglou Receives Zenith Fellows Award to Advance Alzheimer’s Research
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 22, 2025, 10:46Conversation with Ferran Nadeu – Touch Haematology Future Leader 2025
-
Oct 22, 2025, 10:32Lynn Malec - The New Director of the CCBD and Pharmacy at Children's Wisconsin
-
Oct 22, 2025, 09:41Deanna Joseph: Feeling Inspired and Deeply Grateful After Attending the 2025 HTRS SEARCH Workshop
-
Oct 22, 2025, 08:41Maryum Salim Reflects on Her Experience at the HTRS SEARCH Workshop
-
Oct 22, 2025, 08:36Emilya Huseynova to Speak at AABB 2025